{
    "2021-09-15": [
        [
            {
                "time": "2021-02-10",
                "original_text": "Thermo Fisher's Oncomine Dx Gets CDx Approval From MHLW",
                "features": {
                    "keywords": [
                        "Thermo Fisher",
                        "Oncomine Dx",
                        "CDx",
                        "MHLW"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-01-21",
                "original_text": "After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "US Government",
                        "Eli Lilly",
                        "COVID-19",
                        "therapy"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-22",
                "original_text": "The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Regeneron",
                        "COVID-19",
                        "drug deal",
                        "Calliditas",
                        "Theravance",
                        "IPOs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2021-01-25",
                "original_text": "UPDATE 1-U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy",
                "features": {
                    "keywords": [
                        "U.S.",
                        "Eli Lilly",
                        "Regeneron",
                        "COVID-19",
                        "therapy"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-26",
                "original_text": "Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "U.S. government",
                        "COVID-19",
                        "etesevimab",
                        "$330 million"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-01-27",
                "original_text": "Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19",
                "features": {
                    "keywords": [
                        "Lilly",
                        "388,000 doses",
                        "etesevimab",
                        "U.S. government",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}